(Q37494634)

20 August 2017

1 reference

title

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. (English)

1 reference

20 August 2017

1

Charles Erlichman

1 reference

PubMed ID

19466875

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Investigational Drugs

20 August 2017

1 reference

20 August 2017

18

1 reference

20 August 2017

861-868

1 reference

20 August 2017

6

1 reference

The Hsp90 chaperone machinery

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Structure and mechanism of the Hsp90 molecular chaperone machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

New insights into the mechanism of heat shock response activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Cooperative binding of Drosophila heat shock factor to arrays of a conserved 5 bp unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Heat shock genes - integrating cell survival and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

The cellular "networking" of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Cisplatin abrogates the geldanamycin-induced heat shock response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902953699

10.1517/13543780902953699

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19466875